Effect of Amino Acid Substitutions on Biological Activity of Antimicrobial Peptide: Design, Recombinant Production, and Biological Activity.

Parvaneh Panahi Chegini, Iraj Nikokar, Maryam Tabarzad, Sobhan Faezi, Arash Mahboubi
Author Information
  1. Parvaneh Panahi Chegini: Department of Medicinal Biotechnology, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  2. Iraj Nikokar: Department of Medicinal Biotechnology, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  3. Maryam Tabarzad: Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  4. Sobhan Faezi: Medical Biotechnology Research Center, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran.
  5. Arash Mahboubi: Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

Recently, antimicrobial peptides have been introduced as potent antibiotics with a wide range of antimicrobial activities. They have also exhibited other biological activities, including anti-inflammatory, growth stimulating, and anti-cancer activities. In this study, an analog of Magainin II was designed and produced as a recombinant fusion protein. The designed sequence contained 24 amino acid residues (P24), in which Lys, His, Ser residues were substituted with Arg and also, hydrophobic Phe was replaced with Trp. Recombinant production of P24 in BL21 using pTYB21, containing chitin binding domain and intein sequence at the N-terminus of the peptide gene, resulted in 1 μg mL product from culture. Chitin column chromatography, followed by online peptide cleavage with thiol reducing agent was applied to purify the peptide. Antimicrobial activity was evaluated using five bacteria strains including and . Designed AMP exhibited promising antimicrobial activities with low minimum inhibitory concentration, in the range of 64-256 µg/mL. P24 showed potent antimicrobial activity preferably against Gram-positive bacteria, and more potent than pexiganan as a successful Magainin II analog for topical infections. In general, further modification can be applied to improve its therapeutic index.

Keywords

References

  1. Biochemistry (Mosc). 2016 Mar;81(3):187-200 [PMID: 27262188]
  2. Antimicrob Agents Chemother. 1999 Apr;43(4):782-8 [PMID: 10103181]
  3. Biochim Biophys Acta Biomembr. 2018 Aug;1860(8):1502-1516 [PMID: 29750913]
  4. Sci Rep. 2015 May 18;5:9761 [PMID: 25985150]
  5. J Chem Inf Model. 2013 Dec 23;53(12):3280-96 [PMID: 24279498]
  6. PLoS One. 2014 Jul 14;9(7):e101742 [PMID: 25019413]
  7. J Microbiol Biotechnol. 2010 Feb;20(2):350-5 [PMID: 20208440]
  8. J Biol Chem. 1996 Sep 6;271(36):22159-68 [PMID: 8703028]
  9. Mol Cell Endocrinol. 2000 Dec 22;170(1-2):163-74 [PMID: 11162900]
  10. Protein Expr Purif. 2011 Dec;80(2):260-7 [PMID: 21843642]
  11. Eur J Med Chem. 2017 Jan 27;126:456-463 [PMID: 27912176]
  12. Methods Mol Biol. 2015;1268:43-66 [PMID: 25555720]
  13. Biophys J. 2009 Mar 4;96(5):1815-27 [PMID: 19254540]
  14. Iran J Pharm Res. 2019 Summer;18(3):1264-1276 [PMID: 32641937]
  15. Protein Expr Purif. 2005 Feb;39(2):160-8 [PMID: 15642466]
  16. Methods Enzymol. 2015;559:111-25 [PMID: 26096506]
  17. PLoS One. 2013;8(3):e59305 [PMID: 23527157]
  18. Protein Expr Purif. 2008 Feb;57(2):303-11 [PMID: 17977015]
  19. Biochim Biophys Acta. 2009 Aug;1788(8):1680-6 [PMID: 19010301]
  20. Protein Expr Purif. 2001 Aug;22(3):467-71 [PMID: 11483010]
  21. Iran J Pharm Res. 2017 Winter;16(1):297-305 [PMID: 28496483]
  22. Methods Mol Biol. 2017;1548:23-34 [PMID: 28013494]
  23. Methods Mol Biol. 2017;1548:3-22 [PMID: 28013493]
  24. Sci Rep. 2016 Feb 25;6:21839 [PMID: 26912180]
  25. Proteins. 1995 Jun;22(2):182-6 [PMID: 7567965]
  26. Gene. 2018 Sep 10;671:1-9 [PMID: 29859288]
  27. J Chromatogr A. 2011 May 6;1218(18):2553-60 [PMID: 21397239]
  28. Appl Microbiol Biotechnol. 2010 Jun;87(2):479-89 [PMID: 20449740]
  29. Peptides. 2012 Oct;37(2):207-15 [PMID: 22800692]
  30. Front Immunol. 2017 Oct 13;8:1320 [PMID: 29081781]
  31. Adv Drug Deliv Rev. 2014 Nov 30;78:28-45 [PMID: 25453271]
  32. Biotechnol Appl Biochem. 2019 Mar;66(2):209-215 [PMID: 30471160]
  33. Methods Mol Biol. 2010;618:61-76 [PMID: 20094858]
  34. Antimicrob Agents Chemother. 2013 Jun;57(6):2511-21 [PMID: 23507278]
  35. Methods Mol Biol. 2017;1548:427-435 [PMID: 28013523]
  36. Clin Infect Dis. 2009 Dec 1;49(11):1749-55 [PMID: 19857164]
  37. Protein Sci. 2005 Jun;14(6):1387-95 [PMID: 15883185]
  38. Pharmaceuticals (Basel). 2015 Nov 16;8(4):711-57 [PMID: 26580629]
  39. J Antimicrob Chemother. 2014 Jan;69(1):121-32 [PMID: 23946320]
  40. Proc Natl Acad Sci U S A. 1988 Feb;85(3):910-3 [PMID: 3277183]
  41. J Chem Theory Comput. 2014 Oct 14;10(10):4745-58 [PMID: 26588162]

Word Cloud

Created with Highcharts 10.0.0antimicrobialactivitiespeptidepotentP24RecombinantAntimicrobialrangealsoexhibitedincludinganalogMagaininIIdesignedsequenceacidresiduesproductionusingbindingdomainChitinappliedactivitybacteriaAminoBiologicalActivityRecentlypeptidesintroducedantibioticswidebiologicalanti-inflammatorygrowthstimulatinganti-cancerstudyproducedrecombinantfusionproteincontained24aminoLysSersubstitutedArghydrophobicPhereplacedTrpBL21pTYB21containingchitininteinN-terminusgeneresulted1μgmLproductculturecolumnchromatographyfollowedonlinecleavagethiolreducingagentpurifyevaluatedfivestrainsDesignedAMPpromisinglowminimuminhibitoryconcentration64-256µg/mLshowedpreferablyGram-positivepexiganansuccessfultopicalinfectionsgeneralmodificationcanimprovetherapeuticindexEffectAcidSubstitutionsPeptide:DesignProductionsubstitutionInteinlinker

Similar Articles

Cited By